After a quarter of century of rapid technological advances, research has revealed the complexity of cancer, a disease intimately related to the dynamic transformation of the genome. However, the full understanding of the molecular onset of this disease is still far from achieved and the search for mechanisms of treatment will follow closely. It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer. In fact, the National Cancer Institute predicts that over the next years, nanotechnology will result in important advances in early detection, molecular imaging, targeted and multifunctional therapeutics, prevention and control of cancer. Nanotechnology offers numerous tools to diagnose and treat cancer, such as new imaging agents, multifunctional devices capable of overcome biological barriers to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, and devices capable of predicting molecular changes to prevent action against precancerous cells. Nanomaterials-based delivery systems in Theranostics (Diagnostics & Therapy) provide better penetration of therapeutic and diagnostic substances within the body at a reduced risk in comparison to conventional therapies. At the present time, there is a growing need to enhance the capability of theranostics procedures where nanomaterials-based sensors may provide for the simultaneous detection of several gene-associated conditions and nanodevices with the ability to monitor real-time drug action. These innovative multifunctional nanocarriers for cancer theranostics may allow the development of diagnostics systems such as colorimetric and immunoassays, and in therapy approaches through gene therapy, drug delivery and tumor targeting systems in cancer. Some of the thousands and thousands of published nanosystems so far will most likely revolutionize our understanding of biological mechanisms and push forward the clinical practice through their integration in future diagnostics platforms. Nevertheless, despite the significant efforts towards the use of nanomaterials in biologically relevant research, more in vivo studies are needed to assess the applicability of these materials as delivery agents. In fact, only a few went through feasible clinical trials. Nanomaterials have to serve as the norm rather than an exception in the future conventional cancer treatments. Future in vivo work will need to carefully consider the correct choice of chemical modifications to incorporate into the multifunctional nanocarriers to avoid activation off-target, side effects and toxicity. Moreover the majority of studies on nanomaterials do not consider the final application to guide the design of nanomaterial. Instead, the focus is predominantly on engineering materials with specific physical or chemical properties. It is imperative to learn how advances in nanosystem’s capabilities are being used to identify new diagnostic and therapy tools driving the development of personalized medicine in oncology; discover how integrating cancer research and nanotechnology modeling can help patient diagnosis and treatment; recognize how to translate nanotheranostics data into an actionable clinical strategy; discuss with industry leaders how nanotheranostics is evolving and what the impact is on current research efforts; and last but not least, learn what approaches are proving fruitful in turning promising clinical data into treatment realities.

Nanotheranostics is a recent medical field which integrates diagnostic imaging protocols and therapeutic functions to monitor real time drug release in the body and distribution to the target site. The combined processes allow technicians to observe the effectiveness of a specifically designed drug candidate and predict its possible side effects. All these features help clinicians in optimizing treatment options for cancer and other diseases for the individual patient. Current research is tailored to individual therapy because each drug may display a variety of responses depending on variations in an individual’s genetics and subsequently, their clinical biochemistry. Many tumors are still challenging for therapists in terms of available treatment and nanotheranostic strategies may help them to combat cancer more efficiently. Advances in Cancer Nanotheranostics for Experimental and Personalized Medicine presents information about current theranostic technologies in use at clinics and recent research on nanotheranostic applications, with a focus on cancer treatment. Information is presented in seven organized chapters that cover the basics of cancer nanotheranostics, tumor microenvironmental factors, gene therapy and gene delivery concepts, and the combined application of diagnostic imaging with cancer chemotherapy. A chapter focusing on the role of non-coding MRNAs in breast cancer carcinogenesis is also included, giving readers a glimpse of the complexities in the molecular biology of cancer which drive the need for new theranostic technologies. The book is of interest to medical professionals (including oncologists and specialists in internal medicine), diagnostic imaging technicians, and researchers in the fields of pharmacology, molecular biology and nuclear medicine.

Cancer Nanotheranostics, Volume 2 continues the discussion of the important work being done in this field of cancer nanotechnology. The contents of these two volumes are explained in detail as follows. In the first volume of Cancer Nanotheranostics, we discuss the role of different nanomaterials for cancer therapy including lipid-based nanomaterials, protein and peptide-based nanomaterials, polymer-based nanomaterials, metal-organic nanomaterials, porphyrin-based nanomaterials, metal-based nanomaterials, silica-based nanomaterials, exosome-based nanomaterials, and nano-antibodies. This important second volume discusses nano-based diagnosis of cancer, nano-oncology for clinical applications, nano-immunotherapy, nano-based photothermal cancer therapy, nanoerythrosomes for cancer drug delivery, regulatory perspectives of nanomaterials, limitations of cancer nanotheranostics, safety of nanobiomaterials for cancer nanotheranostics, multifunctional nanomaterials for targeting cancer nanotheranostics, and the role of artificial intelligence in cancer nanotheranostics. Volume 2 is a vital continuation of this two-volume set. Together, these two volumes create a comprehensive and unique examination of this important area of research.

Nanotechnology is an interdisciplinary research field that integrates chemistry, engineering, biology, and medicine. Nanomaterials offer tremendous opportunity as well as challenges for researchers. Of course, cancer is one of the world's most common health problems, responsible for many deaths. Exploring efficient anticancer drugs could revolutionize treatment options and help manage cancer mortality. Nanomedicine plays a significant role in developing alternative and more effective treatment strategies for cancer theranostics. This book mainly focuses on the emerging trends using nanomaterials and nanocomposites as alternative anticancer material’s. The book is divided into three main topic areas: how to overcome existing traditional approaches to combat cancer, applying multiple mechanisms to target the cancer cells, and how nanomaterials can be used as effective carriers. The contents highlight recent advances in interdisciplinary research on processing, morphology, structure, and properties of nanostructured materials and their applications to combat cancer.Cancer Nanotheranostics is comprehensive in that it discusses all aspects of cancer nanotechnology. Because of the vast amount of information, it was decided to split this material into two volumes. In the first volume of Cancer Nanotheranostics, we discuss the role of different nanomaterials for cancer therapy, including lipid-based nanomaterials, protein and peptide-based nanomaterials, polymer-based nanomaterials, metal-organic nanomaterials, porphyrin-based nanomaterials, metal-based nanomaterials, silica-based nanomaterials, exosome-based nanomaterials and nano-antibodies. In the second volume, we discuss the nano-based diagnosis of cancer, nano-oncology for clinical applications, nano-immunotherapy, nano-based photothermal cancer therapy, nano-erythrosomes for cancer drug delivery, regulatory perspectives of nanomaterials, limitations of cancer nanotheranostics, the safety of nano-biomaterials for cancer nanotheranostics, multifunctional nanomaterials for targeting cancer nanotheranostics, and the role of artificial intelligence in cancer nanotheranostics.

Nano drug-delivery systems responding to cellular local stimuli, such as pH, temperature and reductive agent's activation, i.e. enzymes, could effectively provide passive-mode desirable release but fail in disease treatment following the biological rhythms of brain tumor. This book is a compilation of research development lead by expert researchers and it establishes a single reference module. It addresses, for the first time, all translational aspects and clinical perspectives of physically stimulated breast-cancer nanotheranostics from a wide-ranging and multidisciplinary perception providing unrivalled and comprehensive knowledge in the field.

Advances in Cancer Research, Volume 139, provides invaluable information on the exciting and fast-moving field of cancer research. Original reviews are presented on a variety of topics relating to the rapidly developing intersection between nanotechnology and cancer research, with unique sections in the new release focusing on Exosomes as a theranostic for lung cancer, Nanotechnology and cancer immunotherapy, Ultrasound imaging agents and delivery systems, Dendronized systems for the delivery of chemotherapeutics, Thermosensitive liposomes for image-guided drug delivery, Supramolecular Chemistry in Tumor Analysis and Drug Delivery, Gold nanoparticles for delivery of cancer therapeutics, and Single cell barcode microchip for cancer research and therapy. Provides the latest information on cancer research Offers outstanding and original reviews on a range of cancer research topics Serves as an indispensable reference for researchers and students alike

Handbook of Nanomaterials for Cancer Theranostics focuses on recent developments in advanced theranostic nanomedicines from a chemical and biological perspective where the advantages of theranostics are achieved by combining multiple components. The authors explore the pros and cons of theranostic nanomaterials developed in cancer research in the last 15 years, with the different strategies compared and scrutinized. In addition, the book explores how nanomaterials may overcome the regulatory hurdles facing theranostic nanomedicines. This is an important research reference for postgraduates and researchers in nanomedicine and cancer research who want to learn more on how nanomaterials can help create more effective cancer treatments. - Highlights the development of smart theranostic nanomaterials to tackle biomedical problems in cancer therapy and diagnostics - Explores the regulatory hurdles facing theranostic nanomedicine - Discusses how the use of nanomaterials can help create more effective cancer treatments

The application of nanotechnology in the biomedical field, known as nanomedicine, has gained much interest in the recent past as a versatile strategy for selective drug delivery and diagnostic purposes. The nanotheranostic approach, which aims to combine both therapeutic and imaging/diagnostic functionalities, is characterized by a strong pluridisciplinarity where the chemistry of materials, bioconjugate chemistry, pharmaceutical technology, drug delivery, imaging, and pharmacology, work together. Nanotheranostics combine simultaneous non-invasive diagnosis and treatment of diseases with the exciting possibility to monitor drug release and distribution in real time; thus offering the opportunity to optimize treatment outcomes in cancer and other severe diseases. Clinical applications of nanotheranostics would enable earlier detection and treatment of diseases, and earlier assessment of the response, thus allowing to identify patients which would potentially respond to therapy and have higher possibilities of a favorable outcome.Nanotheranostics for Personalized Medicine presents an integrated and transdisciplinary description of nanotheranostics. It provides principles of imaging techniques and concrete examples of advances and challenges in the development of nanotheranostics for personalized medicine.This book is written for students (Bachelors to Doctoral level) as well as experienced researchers, in academia or the industry, interested in this emerging concept in the nanomedicine field.

This Brief provides a clear insight of the recent advances in the field of cancer theranostics with special emphasis upon nano scale carrier molecules (polymeric, protein and lipid based) and imaging agents (organic and inorganic).

In recent years, nanoparticles—bionanomaterials with specific physicochemical properties—have gained a great deal of scientific interest owing to their unique structure. Nanoparticle-based drugs are now widely regarded as a safer, more precise, and more effective mode of cancer therapy, considering their ability to enhance drug bioavailability, improve site-specific drug delivery, and protect nontarget tissues from toxic therapeutic drugs. This book compiles and details cutting-edge research in nanomedicine from an interdisciplinary team of international cancer researchers who are currently revolutionizing drug delivery techniques through the development of nanomedicines and nanotheranostics. Edited by Hala Gali-Muhtasib and Racha Chouaib, two prominent cancer researchers, this book will appeal to anyone involved in nanotechnology, cancer therapy, or drug delivery research.